These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Acute development of multiple keratoacanthomas and squamous cell carcinomas after treatment with infliximab.
    Author: Esser AC, Abril A, Fayne S, Doyle JA.
    Journal: J Am Acad Dermatol; 2004 May; 50(5 Suppl):S75-7. PubMed ID: 15097933.
    Abstract:
    Infliximab, a chimeric mouse-human monoclonal antibody, blocks the action of tumor necrosis factor-alpha and is a highly effective treatment for several inflammatory disorders, including inflammatory bowel disease and rheumatoid arthritis. Although safety data are encouraging, immunosuppressive sequelae may result. We report the acute development of multiple squamous cell carcinomas and keratoacanthomas in a patient receiving infliximab for rheumatoid arthritis.
    [Abstract] [Full Text] [Related] [New Search]